PROM1 and liver cancer: A recent study by Karabicici et al. showed that Doxorubicin treatment induced senescence in both liver cancer stem cells (EpCAM+/CD133+) as well as in a non-stem-cell population (EpCAM-/CD133-nonstem) in the Huh7 cell line with a concomitant increase in the reprogramming genes (SOX2, KLF4, c-MYC), liver stemness-related genes, (EpCAM, CK19), and ANXA3 in those cell populations [34].